Form 4: Merck EVP Sells Shares in Pre-Arranged Transaction
Insider Transaction Report
Merck & Co., Inc.'s EVP, Chief Information & Digital Officer, David Michael Williams, sold 8,614 shares of common stock for approximately $720,000.
Summary
- David Michael Williams, Executive Vice President, Chief Information & Digital Officer of Merck & Co., Inc. (MRK), sold 8,614 shares of common stock.
- The transaction occurred on November 3, 2025.
- The shares were sold at a weighted average price of $83.5895 per share, with individual transaction prices ranging from $83.5400 to $83.6200.
- The total value of the shares sold is approximately $720,000.
- Following the transaction, Mr. Williams beneficially owns 24,578.031 shares of Merck common stock.
- The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.
- Holdings include shares acquired through dividend reinvestment transactions.
Sentiment
Score: 5
Explanation: This is a routine Form 4 filing reporting an insider stock sale, often pre-scheduled under a 10b5-1 plan. It does not provide new information about the company's performance or outlook, thus having a neutral sentiment.
Future Outlook
NA
Industry Context
This filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The reported transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 11/03/2025 | Indicates a pre-planned sale, which typically reduces the implication that the executive is timing the sale based on non-public information, aligning with good corporate governance practices for insider transactions. |
Stakeholder Impact
- Shareholders: The sale is a routine, pre-scheduled transaction by an executive and is unlikely to signal a change in company fundamentals or have a significant impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 11/03/2025 | Date of earliest transaction (sale of common stock) |
| 11/04/2025 | Signature date of the reporting person's attorney-in-fact |
Keywords
Merck, MRK, Insider Trading, Stock Sale, Executive Compensation, Form 4, David Michael Williams, Pharmaceutical, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.